BUSINESS

• Latuda Use Patent Suit Could Wrap Up in December: Sumitomo Dainippon Chief
  May 14, 2018

• Towa Wins Top Court Victory over Elplat Patent
  May 14, 2018

• Kyorin Holdings Aims to Boost New Drug Sales to Over 50% of Overall Sales by FY2019: Pres.
  May 14, 2018

• Sumitomo Dainippon’s Sales Hike 14.3% Buoyed by Latuda
  May 14, 2018

• Opdivo Sales Dip 13% despite 1.5-Fold Volume Growth: Ono
  May 11, 2018

• Astellas Gets Rights to Urology Drug Rosiptor in Asia-Pacific Region
  May 11, 2018

• Ono to Boost Oncology Reps to Prep for Opdivo Label Expansions
  May 11, 2018

• YL Biologics Files Enbrel Biosimilar in Japan
  May 11, 2018

• MSD Japan Seeks Adjuvant Melanoma Nod for Keytruda
  May 11, 2018

• Takeda Confident It Can Reduce Debt Quickly after Shire Takeover: CEO
  May 11, 2018

• Shire Buyout a Must for Takeda’s Leap in Global Arena: Board Chair
  May 10, 2018

• Shionogi Earmarks 20 Billion Yen in Strategic R&D Investment
  May 10, 2018

• Shionogi’s Net Profit Crosses 100 Billion Yen Mark in FY2017
  May 10, 2018

• Takeda’s Shire Deal Inspiring for Japan Industry Peers: Mitsubishi Tanabe Chief
  May 10, 2018

• Mitsubishi Tanabe Logs Record Sales, but Profits Sag on Higher R&D/SGA Costs
  May 10, 2018

• AbbVie’s JAK1 Inhibitor Upadacitinib Hits Primary Endpoints in PIIb/III Study in Japanese RA Patients
  May 10, 2018

• Taiho’s Lonsurf Extends OS in PIII in Patients with Metastatic Gastric Cancer
  May 10, 2018

• Pfizer Japan Cedes Crown as Top Rep Holder as Global Players Continue to Seek Leaner Sales Force: Survey
  May 9, 2018

• Takeda Attracted to Shire’s High Profitability, Rare Disease Pipeline: CEO
  May 9, 2018

• Quizartinib Prolongs OS in 2nd-Line AML: Daiichi Sankyo
  May 9, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 396
• 397
• 398
• 399
• 400
• 401
• 402
• 403
• 404
• …
• Next ›
• 最終 »